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ABSTRACT 
Purpose: Breathing management can reduce breath-to-breath (intra-fraction) and day-by-day (inter-fraction) 20 
variability in breathing motion whilst utilizing the respiratory motion of internal and external surrogates for 
respiratory guidance. Audiovisual (AV) biofeedback, an interactive personalized breathing motion management 
system, has been developed to improve reproducibility of intra- and inter-fraction breathing motion. However, 
the assumption of the correlation of respiratory motion between surrogates and tumors is not always verified 
during medical imaging and radiation treatment. Therefore, the aim of the study was to test the hypothesis that 25 
the correlation of respiratory motion between surrogates and tumors is the same under free breathing without 
guidance (FB) and with AV biofeedback guidance for voluntary motion management.  
Methods: For 13 lung cancer patients receiving radiotherapy, 2D coronal and sagittal cine-MR images were 
acquired across two MRI sessions (pre- and mid-treatment) with two breathing conditions: (1) FB and (2) AV 
biofeedback, totaling eighty-eight patient measurements. Simultaneously, the external respiratory motion of the 30 
abdomen was measured. The internal respiratory motion of the diaphragm and lung tumor was retrospectively 
measured from 2D coronal and sagittal cine-MR images. The correlation of respiratory motion between 
surrogates and tumors was calculated using Pearson’s correlation coefficient for: (1) abdomen to tumor 
(abdomen-tumor) and (2) diaphragm to tumor (diaphragm-tumor). The correlations were compared between FB 
and AV biofeedback using several metrics: abdomen-tumor and diaphragm-tumor correlations with/without ≥5 35 
mm tumor motion range and with/without adjusting for phase shifts between the signals.  
Results: Compared to FB, AV biofeedback improved abdomen-tumor correlation by 11% (p=0.12) from 0.53 to 
0.59 and diaphragm-tumor correlation by 13% (p=0.02) from 0.55 to 0.62. Compared to FB, AV biofeedback 
improved abdomen-tumor correlation by 17% (p=0.01) and diaphragm-tumor correlation by 15% (p<0.01) 
whilst correcting 0.3 s (p=0.54) and 0.2 s (p=0.19) phase shifts, respectively. In addition, AV biofeedback with 40 
≥5 mm tumor motion range, compared to FB improved abdomen-tumor correlation by 14% (p=0.18) and 
diaphragm-tumor correlation by 17% (p=0.01). The highest abdomen-tumor and diaphragm-tumor correlations 
were found using ≥5 mm tumor motion range and phase shifts, resulting in a 12% improvement in AV 
biofeedback. 
Conclusions: Our results demonstrated that AV biofeedback improves the correlation of respiratory motion 45 
between surrogates and the tumor. This suggests a need for AV biofeedback for respiratory guidance utilizing 
respiratory surrogates during image-guided and MRI-guided radiotherapy in thoracic regions. 
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I. INTRODUCTION  50 
Breathing variations1, 2 can cause image artifacts3, 4 and blurring of dose distributions5, 6 during medical imaging 
and lung cancer radiotherapy. To overcome this issue, breathing management can reduce breath-to-breath (intra-
fraction) and day-to-day (inter-fraction) variability whilst utilizing respiratory signals for respiratory guidance.5, 
7, 8  
Respiratory surrogates are often used to predict tumor motion during breathing and compensate for tumor 55 
motion with respiratory gating and tracking, and to derive system latency between tumor positioning and 
radiation delivery.9-12 However, tumor motion is not always accurately correlated to the internal/external 
surrogates due to breathing and heartbeat.13-15 In order to avoid mis-targeting during respiratory-gated imaging 
and radiotherapy, the correlation between internal/external surrogates and tumor motion needs to be 
addressed.13, 16, 17  60 
Interactive personalized breathing management systems such as audiovisual (AV) biofeedback have been 
developed to improve reproducibility of intra- and inter-fraction breathing motion. Specifically, Kini et al. 
(2003)7 demonstrated that an audio biofeedback (i.e. “breathe in” or “breathe out” at periodic intervals) can 
improve the reproducibility in the period of the breathing motion, and visual feedback using a bar model can 
improve the reproducibility in the displacement of the breathing motion. George et al. (2006)8 combined an 65 
audio biofeedback with a bar model for AV biofeedback, thus significantly reducing residual motion. In 
addition, Venkat et al. (2008) proposed a wave model composed by an average of ten individual breathing 
cycles and demonstrated its superior performance on a volunteer study in 0.8 mm and 0.2 s with respect to the 
bar model.18 AV biofeedback was also employed by Cui et al. (2010)19 to improve patients’ respiratory 
regularity during 4DCT image acquisition, in order to avoid the artifacts in 4DCT images caused by intra-70 
fraction irregular breathing and allow improved dose delivery accuracy during radiotherapy. Kim et al. (2012)20 
and Lee et al. (2016)21 employed AV biofeedback to improve the reproducibility of diaphragm and lung tumor 
motion measured in MRI. Intra-fraction diaphragm motion reproducibility was improved by 38% in 
displacement and 82% in a breathing period,20 and intra and inter-fraction tumor motion reproducibility was 
improved by 34% and 42% in displacement and 73% and 74% in a breathing period,21 by using AV biofeedback 75 
with respect to a free-breathing acquisition.   
Although it has been demonstrated that AV biofeedback7, 8, 18-21 improves breathing motion reproducibility, 
it has been conjectured that this improvement might be offset by lower surrogate to tumor correlation, as the act 
of biofeedback affects how the patient breathes. A previous study22 on healthy subjects found that the 
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correlation of respiratory motion between internal and external surrogates (diaphragm and abdomen) was the 80 
same with free breathing (FB) and AV biofeedback breathing. However, no patient studies have investigated 
this correlation and the volunteer study did not consider analysis with respect to motion directions and of the 
effects of phase shifts on the correlation. The current study therefore tested the hypothesis that the correlation of 
respiratory motion between internal/external surrogates and tumor is the same with FB and AV biofeedback 
breathing for lung cancer patients. In addition, the effects of phase shifts and tumor motion range on correlations 85 
were investigated along with the variation in correlations between pre- and mid-treatment. 
 
 
II. METHODS 
The following sections describe the acquisition of respiratory-induced motion signals, their synchronization 90 
based on acquisition time and retrospective data analysis by quantifying the correlation of respiratory motion 
between surrogates and tumors. 
 
II.A. Respiratory-induced motion signal acquisition 
Thirteen lung cancer patients (non-small-cell and small-cell lung cancers with stage I‒IIIB of any histology and 95 
a prescription dose of 40‒60 Gy for primary lung cancer) were enrolled in a study approved by the Hunter New 
England Human Research Ethics Committee. The study used eighty-eight coronal and sagittal cine MR image 
datasets acquired with FB and AV biofeedback, which included fifty-two datasets from eight lung cancer 
patients obtained in a previous study.21 A 3 Tesla MRI scanner (Skyra, Siemens Healthcare Erlangen, Germany) 
was used for coronal and sagittal cine-MRI in pre- and mid-treatment (i.e. three to six weeks after the pre-100 
treatment). MRI scans were performed with arms down and head-first supine position. Nine patients completed 
both the first and second MRI sessions and the other three patients withdrew from the study after the first MRI 
session. Simultaneously, external respiratory signals were measured using a physiological measurement unit 
(PMU, A 3 Tesla MRI (Skyra, Siemens Healthcare Erlangen, Germany)) at the chest and a real-time position 
management system (Varian, Palo Alto, USA) at the abdomen. The acquisition of internal/external respiratory-105 
induced motion signals in AV biofeedback is shown in Figure 1. 
 
The workflow of AV biofeedback21 is comprised of three steps (see Figure 1(a)): (1) an individual breathing 
pattern is obtained using external respiratory signals from RPM whilst monitoring the marker block on the 
6 
 
patient’s abdomen, (2) the breathing pattern is displayed on the patient’s visual display using a head-mounted-110 
mirror and screen in the MRI room, and (3) the patient controls their breathing in inhale and exhale breathing 
displacement and period. The setup of the RPM block and camera was consistent during MRI sessions with both 
FB and AV, and also it was consistent across the first and second MRI sessions. Specifically, the RPM block 
and camera were located 2 cm below the navel  due to a 32 channel body coil covers the entire chest and partial 
abdomen and at the end of the MRI couch, respectively.21 115 
Cine-MR images (see Figure 1(a)) and external-PMU signals (see Figure 1(b)) were simultaneously 
obtained at 3.3 Hz and 400 Hz. This was repeated four times in each MRI session (coronal and sagittal cine-
MRI with FB and with AV biofeedback). Meanwhile, external-RPM signals were continuously obtained at 25 
Hz during each MRI session. Then, respiratory motion of the diaphragm (i.e. liver dome)20 and lung tumor (i.e. 
the centroid of tumor contours)21 was directly measured from individual cine-MR images.21 120 
 
II.B. Respiratory motion synchronization 
In this study, respiratory motion from multi-modal systems was synchronized by comparing individual time 
stamps, implemented in Matlab version 8.6.0 (The MathWorks, Natick, USA). The synchronization of the 
respiratory motion was comprised of three steps. 125 
(1) Each external-PMU signal dataset (i.e. four datasets per MRI session) was synchronized by matching 
its first acquisition time point to the corresponding first time point of external-RPM signals and also its 
duration to the same duration of external-RPM signals, thus aligning external-PMU signals with 
respect to external-RPM signals. In this study, external-RPM signals were the only signals used for 
external abdominal motion because they provided absolute displacement in millimeters. PMU signals 130 
provided the motion displacement in an arbitrary unit, which was not sensitive to a baseline drift in 
displacement, but it was sufficient to synchronize two respiratory motions without mismatch.  
(2) Diaphragm and lung tumor motion was directly measured on coronal and sagittal cine-MR images.20, 21 
Lung tumor was automatically contoured using a region growing algorithm and its centroid was used 
for measuring tumor motion.21 Diaphragm motion was also automatically measured at the peak of liver 135 
dome scout.22 Thus, respiratory motions of diaphragm, abdomen and tumor had the same time point 
and duration. 
(3) Diaphragm and tumor motion was linearly interpolated from 3.3 Hz to 25 Hz for further correlation 
calculation, as well as the frequency of abdomen motion (25 Hz). 
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Respiratory motions of abdomen, diaphragm and tumor were described by (i) the abdomen motion in the 140 
anterior-posterior (AP) direction, (ii) the diaphragm motion in the superior-inferior direction (SI), (iii) the tumor 
motion in SI and left-right (LR) directions (i.e. tumor motion from coronal images) and (iv) the tumor motion in 
AP and SI motion (i.e. tumor motion from sagittal images).  
 
II.C. Data analysis 145 
The correlation between two nominated respiratory motions without smoothing was computed by using the 
Pearson’s correlation coefficient in the linear relationship of displacement along the acquisition time. 
Correlations were investigated by quantifying: 
(1) The correlation of respiratory motion between surrogates (abdominal-tumor and diaphragm-tumor) and 
tumor motion across eighty-eight coronal and sagittal datasets.  150 
a. Abdomen motion (AP) to tumor motion (SI and LR) for coronal datasets.  
b. Abdomen motion (AP) to tumor motion (AP and SI) for sagittal datasets. 
c. Diaphragm motion (SI) to tumor motion (SI and LR) for coronal datasets. 
d. Diaphragm motion (SI) to tumor motion (AP and SI) for sagittal datasets. 
(2) Repeated (1) whilst correcting phase shifts (i.e. shifting one time series versus the other one to find the 155 
highest correlation via correcting displacement mismatch). In order to correct phase shifts, the larger 
displacement of two tumor motions (i.e. SI or LR for coronal datasets, and AP or SI for sagittal 
datasets) was applied to the other tumor motion for a consistent phase shift in each coronal and sagittal 
dataset.  
(3) Repeated (1) with seventy-two datasets for a comparison of the correlation between pre- and mid-160 
treatment from nine patients completed both the first and second MRI sessions. 
(4) Repeated (1) with sixty-eight datasets (≥5 mm tumor motion range). 
(5) Repeated (2) with sixty-eight datasets (≥5 mm tumor motion range) adjusted for phase shifts. 
 
The correlation of respiratory motion between surrogates and tumors was individually computed for the 165 
four conditions above. The phase shifts were also measured for the second and fourth conditions. Positive (i.e. 
the same motion direction) and negative (i.e. the opposite motion direction) values were measured by the 
correlation of respiratory motion. To find the maximum correlation, the time series of respiratory-induced 
motion signal acquisitions shifted in a forward direction.  
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The mean of the phase shifts and absolute mean of correlations were reported along with the standard 170 
deviation (STD) and minimum/maximum values. The effects of AV feedback on correlations of tumor motion 
and phase shifts and the variation in pre and mid treatment correlations were compared using a Wilcoxon signed 
rank test with a 5% significance level.23 
 
 175 
III. RESULTS 
Figure 2 shows an example of the respiratory motion measurements, abdomen (AP) obtained from the RPM 
system and diaphragm (SI), tumor (SI) and tumor (LR) motion obtained from a 2D coronal cine-MRI. Most 
tumors have a fairly small LR motion compared to SI and AP motion, however, an example of tumor with a 
large LR motion is shown in Figure 2. 180 
 
The respiratory motion of surrogates can differ from the tumor motion in direction, period and phase (or 
time shift). The respiratory motions of the diaphragm SI (thick dotted line), tumor SI (thin solid line) and tumor 
LR (thin dotted line) move in the same direction but the respiratory motion of the abdomen AP (thick solid line) 
moves in the opposite direction. In addition, there is a small phase shift between diaphragm SI and tumor SI but 185 
a large phase shift for abdomen AP. A small phase shift can be also found between tumor SI and tumor LR. 
External motion at the abdomen is in the AP direction (thick solid line) and internal motion of the diaphragm is 
in the SI direction (thick dotted line). In other words, external motion reaches an anterior position (up) and 
internal motion reaches an inferior position (down) when the patients reaches inhalation.  
 190 
Table 1 shows the correlation of respiratory motion between internal/external surrogates and tumors for 13 
lung cancer patients with multiple acquisition sessions. 
Table 1. The correlation of respiratory motion between surrogates and tumors in a comparison between FB and AV 
biofeedback. Max correlation represents the highest correlation found in two tumor motion directions on 2D cine-MRI: (1) 
SI and LR directions on coronal images, and (2) SI and AP directions on sagittal images. A negative value indicates that 
surrogates and tumor move in the opposite direction. P: Patient, Cor: Coronal, Sag: Sagittal, S: MRI session, AV: AV 
biofeedback and p: a Wilcoxon signed rank test with absolute mean between FB and AV biofeedback.  
Patients Cine-MRI 
Abdomen-tumor correlation Diaphragm-tumor correlation 
FB AV FB AV 
SI LR/AP Max SI LR/AP Max SI LR/AP Max SI LR/AP Max 
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P01 S1 
Cor ‒0.79 ‒0.60 ‒0.79 ‒0.79 ‒0.38 ‒0.79 ‒0.76 ‒0.55 ‒0.76 ‒0.81 ‒0.39 ‒0.81
Sag ‒0.66 ‒0.52 ‒0.66 0.33 ‒0.73 ‒0.73 ‒0.66 ‒0.43 ‒0.66 0.25 ‒0.75 ‒0.75
P01 S2 
Cor ‒0.67 ‒0.08 ‒0.67 ‒0.73 ‒0.68 ‒0.73 ‒0.67 0.00 ‒0.67 ‒0.73 ‒0.63 ‒0.73
Sag 0.08 0.23 0.23 ‒0.53 ‒0.74 ‒0.74 0.09 0.24 0.24 ‒0.50 ‒0.74 ‒0.74
P02 S1 
Cor ‒0.38 0.18 ‒0.38 0.31 ‒0.17 0.31 ‒0.26 0.12 ‒0.26 0.35 ‒0.27 0.35
Sag 0.45 ‒0.66 ‒0.66 0.55 ‒0.06 0.55 0.41 ‒0.59 ‒0.59 0.60 ‒0.10 0.60
P02 S2 
Cor 0.54 ‒0.01 0.54 ‒0.56 ‒0.08 ‒0.56 0.62 ‒0.04 0.62 0.68 ‒0.14 0.68
Sag 0.68 0.56 0.68 0.67 0.39 0.67 0.66 0.54 0.66 0.76 0.39 0.76
P03 S1 
Cor 0.40 ‒0.28 0.40 0.58 ‒0.33 0.58 0.41 ‒0.30 0.41 0.51 ‒0.40 0.51
Sag 0.56 ‒0.55 0.56 0.72 ‒0.29 0.72 0.60 ‒0.59 0.60 0.86 ‒0.53 0.86
P04 S1 
Cor 0.49 0.46 0.49 0.58 0.41 0.58 0.59 0.47 0.59 0.52 0.42 0.52
Sag 0.51 ‒0.01 0.51 0.31 ‒0.42 ‒0.42 0.59 ‒0.07 0.59 0.45 ‒0.35 0.45
P05 S1 
Cor 0.91 ‒0.69 0.91 0.89 ‒0.63 0.89 0.85 ‒0.57 0.85 0.88 ‒0.71 0.88
Sag 0.93 ‒0.05 0.93 0.88 ‒0.41 0.88 0.92 ‒0.03 0.92 0.88 ‒0.57 0.88
P05 S2 
Cor 0.80 ‒0.77 0.80 0.72 ‒0.49 0.72 0.50 ‒0.60 ‒0.60 0.71 ‒0.52 0.71
Sag 0.44 ‒0.12 0.44 0.80 ‒0.56 0.80 0.91 ‒0.26 0.91 0.90 ‒0.66 0.90
P06 S1 
Cor 0.65 ‒0.74 ‒0.74 0.55 ‒0.77 ‒0.77 0.65 ‒0.74 ‒0.74 0.57 ‒0.78 ‒0.78
Sag 0.63 ‒0.59 0.63 0.65 ‒0.50 0.65 0.63 ‒0.70 ‒0.70 0.73 ‒0.57 0.73
P06 S2 
Cor 0.64 ‒0.42 0.64 0.82 ‒0.60 0.82 0.74 ‒0.33 0.74 0.86 ‒0.69 0.86
Sag 0.80 ‒0.65 0.80 0.81 ‒0.46 0.81 0.68 ‒0.49 0.68 0.77 ‒0.39 0.77
P07 S1 
Cor 0.56 0.39 0.56 ‒0.34 0.83 0.83 0.51 0.38 0.51 ‒0.38 0.87 0.87
Sag ‒0.09 0.20 0.20 0.71 0.45 0.71 ‒0.03 0.24 0.24 0.54 0.29 0.54
P08 S1 
Cor 0.33 0.36 0.36 0.29 0.47 0.47 0.30 0.41 0.41 0.27 0.47 0.47
Sag ‒0.27 ‒0.19 ‒0.27 0.18 ‒0.32 ‒0.32 ‒0.26 ‒0.16 ‒0.26 0.22 ‒0.33 ‒0.33
P08 S2 
Cor 0.39 0.54 0.54 0.55 0.17 0.55 0.43 0.51 0.51 0.55 0.13 0.55
Sag 0.09 ‒0.69 ‒0.69 ‒0.37 ‒0.32 ‒0.37 0.19 ‒0.61 ‒0.61 ‒0.37 ‒0.31 ‒0.37
P09 S1 
Cor 0.49 ‒0.24 0.49 0.77 ‒0.39 0.77 0.56 ‒0.27 0.56 0.76 ‒0.44 0.76
Sag 0.59 ‒0.12 0.59 0.70 0.30 0.70 0.61 ‒0.01 0.61 0.85 0.18 0.85
P09 S2 
Cor 0.39 ‒0.09 0.39 0.64 ‒0.28 0.64 0.49 ‒0.01 0.49 0.77 ‒0.29 0.77
Sag 0.38 0.23 0.38 0.72 0.67 0.72 0.40 0.32 0.40 0.78 0.69 0.78
P10 S1 
Cor 0.32 0.14 0.32 0.47 ‒0.14 0.47 0.25 0.10 0.25 0.54 ‒0.15 0.54
Sag 0.54 ‒0.32 0.54 0.54 0.49 0.54 0.53 ‒0.38 0.53 0.58 0.52 0.58
P10 S2 
Cor 0.27 ‒0.04 0.27 0.47 0.27 0.47 0.33 ‒0.05 0.33 0.49 0.21 0.49
Sag 0.43 ‒0.34 0.43 0.38 ‒0.34 0.38 0.40 ‒0.27 0.40 0.39 ‒0.42 ‒0.42
P11 S1 
Cor 0.84 0.64 0.84 0.80 0.21 0.80 0.80 0.53 0.80 0.80 0.22 0.80
Sag 0.58 0.36 0.58 0.70 0.07 0.70 0.70 0.36 0.70 0.80 ‒0.20 0.80
P12 S1 
Cor 0.63 0.16 0.63 0.37 ‒0.26 0.37 0.71 0.08 0.71 0.66 ‒0.41 0.66
Sag 0.25 0.53 0.53 0.37 0.31 0.37 0.40 0.41 0.41 0.35 0.34 0.35
P12 S2 Cor 0.73 ‒0.54 0.73 0.55 ‒0.25 0.55 0.75 ‒0.62 0.75 0.56 ‒0.20 0.56
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Sag 0.45 0.22 0.45 0.55 ‒0.01 0.55 0.52 0.23 0.52 0.60 ‒0.03 0.60
P13 S1 
Cor 0.16 ‒0.01 0.16 0.14 0.21 0.21 0.00 0.14 0.14 0.22 0.20 0.22
Sag 0.31 0.00 0.31 0.35 ‒0.02 0.35 0.48 0.00 0.48 0.36 ‒0.02 0.36
P13 S2 
Cor ‒0.06 ‒0.36 ‒0.36 0.02 0.06 0.06 ‒0.06 ‒0.33 ‒0.33 0.01 0.16 0.16
Sag 0.30 ‒0.10 0.30 ‒0.37 ‒0.04 ‒0.37 0.42 ‒0.19 0.42 ‒0.37 ‒0.09 ‒0.37
Min/Max ‒0.79/0.93 ‒0.79/0.89 ‒0.76/0.92 ‒0.81/0.90
Absolute mean 0.53 0.59 0.55 0.62
STD 0.49 0.54 0.52 0.54
p = 0.12 = 0.02 
 
The correlation of abdomen-tumor with AV biofeedback in Table 1 ranged from ‒0.79 to 0.89 and FB from 
‒0.79 to 0.93 whilst the correlation of diaphragm-tumor with AV biofeedback varied between ‒0.81 and 0.90, 195 
and FB between ‒0.76 and 0.92. Compared to FB, the absolute mean correlation with AV biofeedback was 
improved by 11% (p=0.12) from 0.53 to 0.59 in abdomen-tumor and 13% (p=0.02) from 0.55 to 0.62 in 
diaphragm-tumor. Of the surrogate-tumor correlations, the diaphragm-tumor correlation was higher than the 
abdomen-tumor correlation with both AV biofeedback and FB. 
 200 
Table 2 shows the correlation of abdomen-tumor and diaphragm-tumor whilst correcting phase shifts. 
Table 2. The correlation of abdomen-tumor and diaphragm-tumor with adjusted phase shifts. p: a Wilcoxon 
signed rank test with the absolute mean value for the correlation and the mean value for the phase shifts between 
FB and AV biofeedback. 
Quantitative comparison 
Abdomen-tumor correlation Diaphragm-tumor correlation 
FB AV FB AV 
Correlation 
Min/Max ‒0.82/0.96 ‒0.85/0.96 ‒0.82/0.93 ‒0.86/0.92 
Absolute mean 0.62 0.68 0.62 0.68 
STD 0.60 0.50 0.58 0.47 
p = 0.01 < 0.01 
Phase shifts 
 (s) 
Min/Max 0.08/1.80 0.08/1.45 0.04/0.68 0.04/0.36 
Mean 0.32 0.30 0.20 0.17 
STD 0.32 0.28 0.13 0.09 
p = 0.54 = 0.19 
 
The time series of surrogates were shifted to find the maximum correlation with the tumor. The means of 
the adjusted phase shifts were measured at 0.3 s for abdomen-tumor and 0.2 s for diaphragm-tumor. These phase 
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shifts resulted in a 17% higher correlation from 0.53 (see Table 1) to 0.62 with FB and a 15% higher correlation 205 
from 0.59 (see Table 1) to 0.68 with AV biofeedback for the abdomen-tumor correlation. Similarly they resulted 
in a 13% higher correlation from 0.55 (see Table 1) to 0.62 with FB and a 10% higher correlation from 0.62 (see 
Table 1) to 0.68 with AV biofeedback for the diaphragm-tumor correlation. For both FB and with AV 
biofeedback, the correlation for abdomen-tumor was the same as the correlation for diaphragm-tumor, however, 
AV biofeedback produced a 10% higher correlation for surrogate-tumor compared with FB alone. 210 
 
Table 3 shows the correlation of abdomen-tumor and diaphragm-tumor with adjusted phase shifts across 
pre- and mid-treatment.  Seventy-two of eighty-eight acquisitions from nine patients except for P03, P04 and 
P06 (see Table 1) were analyzed to compare variability on the correlation across pre- and mid-treatment. There 
was no significant difference in the correlations between pre- and mid-treatment, which indicates that the 215 
correlation of abdomen-tumor and diaphragm-tumor does not significantly vary across the two MRI sessions 
with both FB and AV biofeedback.   
Table 3. The correlation of abdomen-tumor and diaphragm-tumor with adjusted phase shifts across pre- and mid-
treatment. Pre: pre-treatment, Mid: mid-treatment, Both: pre- and mid-treatment, and p: a Wilcoxon signed rank 
test between pre- and mid-treatment.  
Quantitative 
comparison 
Abdomen-tumor correlation Diaphragm-tumor correlation 
FB AV FB AV 
Pre Mid Both Pre Mid Both Pre Mid Both Pre Mid Both 
Correlation 
Min 
/Max 
‒0.78 
/0.96 
‒0.77 
/0.95 
‒0.78
/0.96
‒0.85 
/0.93 
‒0.54 
/0.96 
‒0.85
/0.96 
‒0.76 
/0.93 
‒0.74 
/0.91 
‒0.76 
/0.93 
‒0.86 
/0.88 
‒0.48 
/0.92  
‒0.86
/0.92
Absolute 
mean 0.65 0.59 0.62 0.65 0.67 0.65 0.62 0.63 0.62 0.67 0.68 0.67 
STD 0.61 0.56 0.58 0.52 0.46 0.57 0.59 0.54 0.49 0.58 0.35 0.49 
p = 0.96 = 0.52 = 0.64 = 0.14 
Phase shifts 
 (s) 
Min 
/Max 
0.08 
/1.06 
0.08 
/1.80 
0.08 
/1.80
0.08 
/0.92 
0.08 
/1.45 
0.08 
/1.45 
0.04 
/0.32 
0.04 
/0.44 
0.04 
/0.44 
0.04 
/0.36 
0.04 
/0.36 
0.04 
/0.36
Mean 0.27 0.35 0.31 0.31 0.33 0.32 0.17 0.20 0.19 0.18 0.16 0.17 
STD 0.26 0.42 0.34 0.25 0.39 0.31 0.10 0.13 0.11 0.11 0.09 0.10 
p = 0.08 = 0.60 = 0.20 = 0.40 
 
Figure 3 shows the correlation of respiratory motion between surrogates and tumor from sixty-eight 
acquisitions with ≥5 mm tumor motion range. Absolute correlation values were used to demonstrate a 220 
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comparison of its (higher or lower) correlation between FB and AV biofeedback across abdomen-tumor and 
diaphragm-tumor. 
 
In the correlation two subgroups between sixty-eight datasets (≥5 mm tumor motion range) and eighty-eight 
datasets (> 0 mm tumor motion range), AV biofeedback, compared to FB, improved abdomen-tumor correlation 225 
by 14% (p=0.18) from 0.57 to 0.65 and diaphragm-tumor correlation by 17% (p=0.01) from 0.59 to 0.69. In 
addition, the correlations from the acquisitions with ≥5 mm tumor motion were compared to the correlations 
from all datasets in Table 1. Higher correlations were observed with ≥5 mm tumor motion with FB by 8% of 
abdomen-tumor correlation from 0.53 to 0.57 and 7% of diaphragm-tumor correlation from 0.55 to 0.59, and 
also with AV biofeedback, 10% of abdomen-tumor correlation from 0.59 to 0.65 and 11% of diaphragm-tumor 230 
correlation from 0.62 to 0.69. 
 
Table 4 shows the correlation of abdomen-tumor and diaphragm-tumor with adjusted phase shifts and ≥5 
mm tumor motion range. 
Table 4. The correlation of abdomen-tumor and diaphragm-tumor with adjusted phase shifts and ≥5 mm tumor 
motion range. p: a Wilcoxon signed rank test between FB and AV biofeedback. 
Quantitative comparison  
Abdomen-tumor correlation Diaphragm-tumor correlation 
FB AV FB AV 
Correlation 
Min/Max ‒0.82/0.96 ‒0.85/0.96 ‒0.82/0.93 ‒0.85/0.92 
Absolute mean 0.67 0.75 0.68 0.76 
STD 0.62 0.46 0.61 0.45 
p = 0.02 < 0.01 
 235 
With ≥5 mm tumor motion range, the phase shift produced higher correlations in both abdomen-tumor and 
diaphragm-tumor correlations, 8% (p=0.02) from 0.62 (see Table 2) to 0.67 and 10% (p<0.01) from 0.62 (see 
Table 2) to 0.68 improvements in FB and AV biofeedback, respectively. With a minimal increase of phase 
shifts, an average of 2 – 3 milliseconds (see Table 2), the abdomen-tumor and diaphragm-tumor correlations 
were similarly improved in both FB and AV biofeedback but remained 12% higher  with AV biofeedback 240 
compared with FB alone. 
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IV. DISCUSSION  
Lung tumor displacement and baseline drift due to intra- and inter-fraction breathing motion variability, may 245 
lead to a failure in accurate radiation delivery and tumor motion predictions.9, 12 Most breathing management 
techniques rely on internal and external surrogates to improve tumor motion controlled and predictions, but the 
respiratory motion of surrogates does not always accurately match tumor motion.  
In the literature, the AV biofeedback system has been shown to improve the reproducibility of breathing 
motion with respect to FB,24 and an internal/external correlation between FB and AV biofeedback was found to 250 
be consistent for healthy volunteers.22 However, no studies on the correlation between surrogate and tumor 
motion with AV biofeedback have been reported. Therefore, in this study, we used MR images to study the 
correlation of respiratory motion between the surrogates and the tumors with and without AV biofeedback. As 
shown in Table 1, for all the acquired patients over different sessions, the correlation between the analyzed 
surrogates (i.e. abdomen and diaphragm) and the tumor motion increased over 10% with AV biofeedback in 255 
comparison to the standard FB acquisition. This correlation can be additionally improved by compensating for 
phase shifts to allow the maximum correlation (see Table 2). The phase shifts for FB and AV biofeedback 
appeared to be similar, but slightly smaller with AV than FB. In this case, the correlation increased in FB and 
AV biofeedback for both abdomen-tumor and diaphragm-tumor pairs. Specifically, the phase shifts were 0.3 s 
for abdomen-tumor and 0.2 s for diaphragm-tumor, suggesting the need to compensate for these time 260 
discrepancies in order to further improve respiratory gating and tracking efficacy and tumor motion predictions. 
In this study, MRI scans were performed with arms down and head-first supine position. However, we believe 
that even with arms up, AV feedback could potentially improve the correlation between internal/external 
surrogate motion and lung tumor motion and future studies could investigate the impact of AV biofeedback with 
different patient positions. 265 
The positive effect of AV biofeedback with respect to FB in improving the correlation of tumor motion 
with surrogates is apparent on patients with a larger range of motion (≥ 5 mm),10 suggesting the potential utility 
of AV biofeedback for patients with a high range of motion. This is due to correlation being affected by (1) 
breathing motion consistency in displacement and period, and (2) tumor motion large enough to clearly 
distinguish each cycle. This study demonstrated higher correlation when tumor motion is ≥ 5 mm due to less 270 
noisy respiratory motion. 
The RPM system is often used to monitor breathing motion for acquiring time-resolved images and 
compensating breathing motion during thoracic imaging, and radiotherapy. In addition, RPM is widely used in 
14 
 
many clinics due to its superior accuracy with absolute displacement in sub-millimeters. However, RPM is an 
independent system to MRI so it is unable to be used to synchronize acquisition time between RPM signals and 275 
MR images. In this study, to synchronize RPM signal to the MR images the RPM was synchronized to the PMU 
system, which uses the time-base of the MRI scanner. So far, only two MRI studies21, 22 have utilized RPM 
signals as inputs of breathing motion guidance because it requires an appropriate innovation in visual guidance 
with MR-compatible materials (i.e. a head-mounted mirror for providing visual guidance and a plastic 
transparent screen for displaying visual guidance with a projector).  RPM can be replaced with other breathing 280 
motion monitoring devices which provide absolute displacement, and with a time-base synchronized to MR 
image acquisition. 
Compared to the motion of internal and external surrogates, tumor motion varies in motion direction and 
phase shift. Thus it is very important that tumor motion is analyzed using 2D cine or 4D images prior to 
predicting tumor location and respiratory-gated radiotherapy. For example, if the tumor is located at (near) the 285 
chest wall, it moves in the direction of chest wall motion, which differs from diaphragm motion and is the same 
as abdominal motion. Thus, individual treatment plans can be customized to improve lung cancer radiotherapy 
outcome, whilst considering respiratory motion management using AV biofeedback. In addition, phase shifts 
between internal/external surrogates and tumors, and their motion direction should be considered to achieve a 
better correlation. 290 
The limitations of the present study were that the diaphragm visibility was restricted on lung tumor images 
depending on the tumor location and the tumor displacement of some patients was considerably small (less than 
2 mm) to distinguish tumor motion from noise, resulting in a tumor motion correlation lower than 0.2. 
Moreover, the respiratory motion of lung and abdominal tumors is dependent on tumor size, location and patient 
respiratory pattern.25 However, the correlation of respiratory motion between surrogates and tumor and the 295 
subsequent effectiveness of the treatment can be further analyzed by selecting patients who may potentially 
require AV biofeedback integrated with clinically available and innovative image-guided tumor motion 
monitoring techniques, such as MRI-guidance.2, 26, 27  
Our results demonstrated that AV biofeedback significantly improved the correlation of respiratory motion 
between surrogates and tumor, thus suggesting the need for the integration of AV biofeedback into external 300 
beam radiotherapy.  
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V. CONCLUSIONS 
This was the first study in which AV biofeedback was used to derive the correlation of respiratory motion 305 
between surrogates and tumors, through the acquisition of fast cine-MRI slices. By utilizing audiovisual 
biofeedback, we demonstrated an improvement of 11% in abdomen to tumor correlation and 13% in diaphragm 
to tumor correlation with respect to a standard free-breathing acquisition, thus suggesting that AV biofeedback 
could be a desirable technique for respiratory guidance during image-guided and MRI-guided radiotherapy in 
thoracic and abdominal regions.  310 
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Figure 1. Respiratory-induced motion acquisitions in AV biofeedback: (a) internal diaphragm (vertical 
rectangle (red)) and lung tumor (circle (blue)) motion measurements, directly measured from coronal 
and sagittal cine-MR images, and (b) external chest and abdomen motion measurements. 
 
Figure 2.  An example respiratory motion obtained from the external measurement: abdomen AP (thick 
solid line) and internal measurements from 2D coronal cine-MRI: diaphragm SI (thick dotted line), tumor 
SI (thin solid line) and tumor LR (thin dotted line). The diaphragm SI motion is smaller than tumor SI and 
LR motions due to the tumor location close to the chest wall and back, where the diaphragm motion is 
limited on lung tumor images. 
 
Figure 3. The correlation of abdomen-tumor and diaphragm-tumor with ≥5 mm tumor motion range.  
On each box, the central mark is the median, the edges of the box are the 25th and 75th percentiles, and 
the end lines after each dotted line extend to the most extreme data points. 
 
Table 1. The correlation of respiratory motion between surrogates and tumors in a comparison between FB and AV biofeedback. 
Max correlation represents the highest correlation found in two tumor motion directions on 2D cine-MRI: (1) SI and LR 
directions on coronal images, and (2) SI and AP directions on sagittal images. A negative value indicates that surrogates and 
tumor move in the opposite direction. P: Patient, Cor: Coronal, Sag: Sagittal, S: MRI session, AV: AV biofeedback and p: a 
Wilcoxon signed rank test with absolute mean between FB and AV biofeedback.  
Patients Cine-MRI 
Abdomen-tumor correlation Diaphragm-tumor correlation 
FB AV FB AV 
SI LR/AP Max SI LR/AP Max SI LR/AP Max SI LR/AP Max 
P01 S1 
Cor ‒0.79 ‒0.60 ‒0.79 ‒0.79 ‒0.38 ‒0.79 ‒0.76 ‒0.55 ‒0.76 ‒0.81 ‒0.39 ‒0.81
Sag ‒0.66 ‒0.52 ‒0.66 0.33 ‒0.73 ‒0.73 ‒0.66 ‒0.43 ‒0.66 0.25 ‒0.75 ‒0.75
P01 S2 
Cor ‒0.67 ‒0.08 ‒0.67 ‒0.73 ‒0.68 ‒0.73 ‒0.67 0.00 ‒0.67 ‒0.73 ‒0.63 ‒0.73
Sag 0.08 0.23 0.23 ‒0.53 ‒0.74 ‒0.74 0.09 0.24 0.24 ‒0.50 ‒0.74 ‒0.74
P02 S1 
Cor ‒0.38 0.18 ‒0.38 0.31 ‒0.17 0.31 ‒0.26 0.12 ‒0.26 0.35 ‒0.27 0.35
Sag 0.45 ‒0.66 ‒0.66 0.55 ‒0.06 0.55 0.41 ‒0.59 ‒0.59 0.60 ‒0.10 0.60
P02 S2 
Cor 0.54 ‒0.01 0.54 ‒0.56 ‒0.08 ‒0.56 0.62 ‒0.04 0.62 0.68 ‒0.14 0.68
Sag 0.68 0.56 0.68 0.67 0.39 0.67 0.66 0.54 0.66 0.76 0.39 0.76
P03 S1 
Cor 0.40 ‒0.28 0.40 0.58 ‒0.33 0.58 0.41 ‒0.30 0.41 0.51 ‒0.40 0.51
Sag 0.56 ‒0.55 0.56 0.72 ‒0.29 0.72 0.60 ‒0.59 0.60 0.86 ‒0.53 0.86
P04 S1 
Cor 0.49 0.46 0.49 0.58 0.41 0.58 0.59 0.47 0.59 0.52 0.42 0.52
Sag 0.51 ‒0.01 0.51 0.31 ‒0.42 ‒0.42 0.59 ‒0.07 0.59 0.45 ‒0.35 0.45
P05 S1 
Cor 0.91 ‒0.69 0.91 0.89 ‒0.63 0.89 0.85 ‒0.57 0.85 0.88 ‒0.71 0.88
Sag 0.93 ‒0.05 0.93 0.88 ‒0.41 0.88 0.92 ‒0.03 0.92 0.88 ‒0.57 0.88
P05 S2 
Cor 0.80 ‒0.77 0.80 0.72 ‒0.49 0.72 0.50 ‒0.60 ‒0.60 0.71 ‒0.52 0.71
Sag 0.44 ‒0.12 0.44 0.80 ‒0.56 0.80 0.91 ‒0.26 0.91 0.90 ‒0.66 0.90
P06 S1 
Cor 0.65 ‒0.74 ‒0.74 0.55 ‒0.77 ‒0.77 0.65 ‒0.74 ‒0.74 0.57 ‒0.78 ‒0.78
Sag 0.63 ‒0.59 0.63 0.65 ‒0.50 0.65 0.63 ‒0.70 ‒0.70 0.73 ‒0.57 0.73
P06 S2 
Cor 0.64 ‒0.42 0.64 0.82 ‒0.60 0.82 0.74 ‒0.33 0.74 0.86 ‒0.69 0.86
Sag 0.80 ‒0.65 0.80 0.81 ‒0.46 0.81 0.68 ‒0.49 0.68 0.77 ‒0.39 0.77
P07 S1 
Cor 0.56 0.39 0.56 ‒0.34 0.83 0.83 0.51 0.38 0.51 ‒0.38 0.87 0.87
Sag ‒0.09 0.20 0.20 0.71 0.45 0.71 ‒0.03 0.24 0.24 0.54 0.29 0.54
P08 S1 
Cor 0.33 0.36 0.36 0.29 0.47 0.47 0.30 0.41 0.41 0.27 0.47 0.47
Sag ‒0.27 ‒0.19 ‒0.27 0.18 ‒0.32 ‒0.32 ‒0.26 ‒0.16 ‒0.26 0.22 ‒0.33 ‒0.33
P08 S2 
Cor 0.39 0.54 0.54 0.55 0.17 0.55 0.43 0.51 0.51 0.55 0.13 0.55
Sag 0.09 ‒0.69 ‒0.69 ‒0.37 ‒0.32 ‒0.37 0.19 ‒0.61 ‒0.61 ‒0.37 ‒0.31 ‒0.37
P09 S1 
Cor 0.49 ‒0.24 0.49 0.77 ‒0.39 0.77 0.56 ‒0.27 0.56 0.76 ‒0.44 0.76
Sag 0.59 ‒0.12 0.59 0.70 0.30 0.70 0.61 ‒0.01 0.61 0.85 0.18 0.85
P09 S2 
Cor 0.39 ‒0.09 0.39 0.64 ‒0.28 0.64 0.49 ‒0.01 0.49 0.77 ‒0.29 0.77
Sag 0.38 0.23 0.38 0.72 0.67 0.72 0.40 0.32 0.40 0.78 0.69 0.78
P10 S1 
Cor 0.32 0.14 0.32 0.47 ‒0.14 0.47 0.25 0.10 0.25 0.54 ‒0.15 0.54
Sag 0.54 ‒0.32 0.54 0.54 0.49 0.54 0.53 ‒0.38 0.53 0.58 0.52 0.58
P10 S2 
Cor 0.27 ‒0.04 0.27 0.47 0.27 0.47 0.33 ‒0.05 0.33 0.49 0.21 0.49
Sag 0.43 ‒0.34 0.43 0.38 ‒0.34 0.38 0.40 ‒0.27 0.40 0.39 ‒0.42 ‒0.42
P11 S1 
Cor 0.84 0.64 0.84 0.80 0.21 0.80 0.80 0.53 0.80 0.80 0.22 0.80
Sag 0.58 0.36 0.58 0.70 0.07 0.70 0.70 0.36 0.70 0.80 ‒0.20 0.80
P12 S1 
Cor 0.63 0.16 0.63 0.37 ‒0.26 0.37 0.71 0.08 0.71 0.66 ‒0.41 0.66
Sag 0.25 0.53 0.53 0.37 0.31 0.37 0.40 0.41 0.41 0.35 0.34 0.35
P12 S2 
Cor 0.73 ‒0.54 0.73 0.55 ‒0.25 0.55 0.75 ‒0.62 0.75 0.56 ‒0.20 0.56
Sag 0.45 0.22 0.45 0.55 ‒0.01 0.55 0.52 0.23 0.52 0.60 ‒0.03 0.60
P13 S1 
Cor 0.16 ‒0.01 0.16 0.14 0.21 0.21 0.00 0.14 0.14 0.22 0.20 0.22
Sag 0.31 0.00 0.31 0.35 ‒0.02 0.35 0.48 0.00 0.48 0.36 ‒0.02 0.36
P13 S2 
Cor ‒0.06 ‒0.36 ‒0.36 0.02 0.06 0.06 ‒0.06 ‒0.33 ‒0.33 0.01 0.16 0.16
Sag 0.30 ‒0.10 0.30 ‒0.37 ‒0.04 ‒0.37 0.42 ‒0.19 0.42 ‒0.37 ‒0.09 ‒0.37
Min/Max ‒0.79/0.93 ‒0.79/0.89 ‒0.76/0.92 ‒0.81/0.90
Absolute mean 0.53 0.59 0.55 0.62
STD 0.49 0.54 0.52 0.54
p = 0.12 = 0.02 
 
 
Table 2. The correlation of abdomen-tumor and diaphragm-tumor with adjusted phase shifts. p: a Wilcoxon signed 
rank test with the absolute mean value for the correlation and the mean value for the phase shifts between FB and 
AV biofeedback. 
Quantitative comparison 
Abdomen-tumor correlation Diaphragm-tumor correlation 
FB AV FB AV 
Correlation 
Min/Max ‒0.82/0.96 ‒0.85/0.96 ‒0.82/0.93 ‒0.86/0.92 
Absolute mean 0.62 0.68 0.62 0.68 
STD 0.60 0.50 0.58 0.47 
p = 0.01 < 0.01 
Phase shifts 
 (s) 
Min/Max 0.08/1.80 0.08/1.45 0.04/0.68 0.04/0.36 
Mean 0.32 0.30 0.20 0.17 
STD 0.32 0.28 0.13 0.09 
p = 0.54 = 0.19 
 
 
Table 3. The correlation of abdomen-tumor and diaphragm-tumor with adjusted phase shifts across pre- and mid-
treatment. Pre: pre-treatment, Mid: mid-treatment, Both: pre- and mid-treatment, and p: a Wilcoxon signed rank 
test between pre- and mid-treatment.  
Quantitative 
comparison 
Abdomen-tumor correlation Diaphragm-tumor correlation 
FB AV FB AV 
Pre Mid Both Pre Mid Both Pre Mid Both Pre Mid Both 
Correlation 
Min 
/Max 
‒0.78 
/0.96 
‒0.77 
/0.95 
‒0.78
/0.96 
‒0.85 
/0.93 
‒0.54 
/0.96 
‒0.85
/0.96 
‒0.76 
/0.93 
‒0.74 
/0.91 
‒0.76 
/0.93 
‒0.86 
/0.88 
‒0.48 
/0.92  
‒0.86
/0.92
Absolute 
mean 0.65 0.59 0.62 0.65 0.67 0.65 0.62 0.63 0.62 0.67 0.68 0.67 
STD 0.61 0.56 0.58 0.52 0.46 0.57 0.59 0.54 0.49 0.58 0.35 0.49 
p = 0.96 = 0.52 = 0.64 = 0.14 
Phase shifts 
 (s) 
Min 
/Max 
0.08 
/1.06 
0.08 
/1.80 
0.08 
/1.80 
0.08 
/0.92 
0.08 
/1.45 
0.08 
/1.45 
0.04 
/0.32 
0.04 
/0.44 
0.04 
/0.44 
0.04 
/0.36 
0.04 
/0.36 
0.04 
/0.36
Mean 0.27 0.35 0.31 0.31 0.33 0.32 0.17 0.20 0.19 0.18 0.16 0.17 
STD 0.26 0.42 0.34 0.25 0.39 0.31 0.10 0.13 0.11 0.11 0.09 0.10 
p = 0.08 = 0.60 = 0.20 = 0.40 
 
 
Table 4. The correlation of abdomen-tumor and diaphragm-tumor with adjusted phase shifts and ≥5 mm tumor 
motion range. p: a Wilcoxon signed rank test between FB and AV biofeedback. 
Quantitative comparison  
Abdomen-tumor correlation Diaphragm-tumor correlation 
FB AV FB AV 
Correlation 
Min/Max ‒0.82/0.96 ‒0.85/0.96 ‒0.82/0.93 ‒0.85/0.92 
Absolute 
mean 0.67 0.75 0.68 0.76 
STD 0.62 0.46 0.61 0.45 
p = 0.02 < 0.01 
 
 
